Gensight Biologics SA

10/07/2026 | Press release | Distributed by Public on 10/07/2026 15:59

GenSight Biologics Reports Cash Position as of September 30, 2026

07 October 2026
  • Financial press releases
  • €8.2 million in gross cash collections from paid early access programs since the start of treatments in March 2026, including €1.7 million during the third quarter
  • Paid early access programs continue to generate cash and support the Company's operating activities.
  • €0.7 million in cash and cash equivalents as of September 30, 2026
Gensight Biologics SA published this content on October 07, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 07, 2026 at 21:59 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]